Clinical Trial: Efficacy and safety of ipilimumab in combination with bevacizumab as first-line treatment in advanced cutaneous and acral melanoma: a prospective, single-arm clinical study (China)

Posted On: 2026-10-12

China, Oct. 12 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Efficacy and safety of ipilimumab in combination with bevacizumab as first-line treatment in advanced cutaneous and acral melanoma: a prospective, single-arm clinical study'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600134147

Registration Time: 2026/10/11

Type: Interventional study

Primary Sponsor: Anyang Tumour Hospital

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=298063

Published by HT Digital Content Services with permission from Health Daily Digest....

Click here to read full article from source

To read the full article or to get the complete feed from this publication, please Contact Us.

Exclusive

Category

Source

Publication

Location

Clinical Trial: Efficacy and safety of ipilimumab in combination with bevacizumab as first-line treatment in advanced cutaneous and acral melanoma: a prospective, single-arm clinical study (China)